This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogen
This SLC22A2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 514-541 amino acids from the C-terminal region of human SLC22A2.
OCT2 antibody, Oct2 antibody, Orct2 antibody, OCT2r antibody, rOCT2 antibody, Pou2f2 antibody, OCT2P antibody, oct1 antibody, wu:fc01b11 antibody, zgc:64076 antibody, slc22a2 antibody, solute carrier family 22 member 2 antibody, solute carrier family 22 (organic cation transporter), member 2 antibody, POU class 2 homeobox 2 antibody, solute carrier family 22 (organic cation transporter), member 2 L homeolog antibody, SLC22A2 antibody, Slc22a2 antibody, POU2F2 antibody, LOC521027 antibody, slc22a2 antibody, slc22a2.L antibody
Background
SLC22A2 mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.